Dandan Dou1,2, Yuge Ji2, Junjie Zheng2, Jingxin Li2, Xiaolong Zhu3, Shuhai Tang4, Hongjuan Wang5, Qin Li2, Haiyan Jing6. 1. Department of Pathology, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, 250021, China. 2. Department of Physiology, School of Basic Medical Science, Shandong University, Jinan, China. 3. Department of Surgery, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, China. 4. Department of Anesthesiology, Qilu Hospital of Shandong University, Jinan, China. 5. Department of Gastroenterology, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China. 6. Department of Pathology, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, 250021, China. haiyanjingbl@163.com.
Abstract
BACKGROUND: Conivaptan, a nonselective antagonist of vasopressin receptors V1a and V2, is the first drug of this class to be used for treating euvolemic and hypervolemic hyponatremia. Recently, increasing evidence supports the involvement of vasopressin in immune responses. AIMS: In this study, we investigated the effect of conivaptan on the modulation of CD4+ T cell homeostasis and the progression of experimental colitis. METHODS: The expression of the V1a receptor on CD4+ T cells was detected by immunofluorescence and western blot. The subset of isolated CD4+ T cells were examined after arginine vasopressin (AVP) incubation. CD4+ T cells were injected into DNBS-induced mice through the tail vein. The severity of colitis was evaluated according to weight, disease activity index (DAI), and morphological injury. Intracellular Ca2+ ([Ca2+]i) signaling in CD4+ T cells was measured using the Fluo-3 AM loading method. T-bet and IFN-γ mRNAs in the colon were detected by real-time polymerase chain reaction (qPCR). RESULTS: We found that CD4+ T cells expressed the V1a receptor. Activation of the V1a receptor significantly promoted the differentiation of CD4+ T cells into T helper 1 (Th1) cells. This process was blocked by conivaptan treatment. However, the activation of the V1a receptor did not evoke an increase in [Ca2+]i in CD4+ T cells. Notably, conivaptan markedly alleviated body weight loss, pathological damage, and expression of T-bet and IFN-γ in the colon of DNBS-treated mice. CONCLUSIONS: For the first time, we report that conivaptan attenuated colitis by inhibiting the differentiation of CD4+ T cells into Th1 cells. Mechanistically, the anti-inflammatory role of conivaptan is independent of [Ca2+]i.
BACKGROUND: Conivaptan, a nonselective antagonist of vasopressin receptors V1a and V2, is the first drug of this class to be used for treating euvolemic and hypervolemic hyponatremia. Recently, increasing evidence supports the involvement of vasopressin in immune responses. AIMS: In this study, we investigated the effect of conivaptan on the modulation of CD4+ T cell homeostasis and the progression of experimental colitis. METHODS: The expression of the V1a receptor on CD4+ T cells was detected by immunofluorescence and western blot. The subset of isolated CD4+ T cells were examined after arginine vasopressin (AVP) incubation. CD4+ T cells were injected into DNBS-induced mice through the tail vein. The severity of colitis was evaluated according to weight, disease activity index (DAI), and morphological injury. Intracellular Ca2+ ([Ca2+]i) signaling in CD4+ T cells was measured using the Fluo-3 AM loading method. T-bet and IFN-γ mRNAs in the colon were detected by real-time polymerase chain reaction (qPCR). RESULTS: We found that CD4+ T cells expressed the V1a receptor. Activation of the V1a receptor significantly promoted the differentiation of CD4+ T cells into T helper 1 (Th1) cells. This process was blocked by conivaptan treatment. However, the activation of the V1a receptor did not evoke an increase in [Ca2+]i in CD4+ T cells. Notably, conivaptan markedly alleviated body weight loss, pathological damage, and expression of T-bet and IFN-γ in the colon of DNBS-treated mice. CONCLUSIONS: For the first time, we report that conivaptan attenuated colitis by inhibiting the differentiation of CD4+ T cells into Th1 cells. Mechanistically, the anti-inflammatory role of conivaptan is independent of [Ca2+]i.
Authors: Johan Burisch; Hillel Vardi; Doron Schwartz; Michael Friger; Gediminas Kiudelis; Juozas Kupčinskas; Mathurin Fumery; Corinne Gower-Rousseau; Laszlo Lakatos; Peter L Lakatos; Renata D'Incà; Alessandro Sartini; Daniela Valpiani; Martina Giannotta; Naila Arebi; Dana Duricova; Martin Bortlik; Stefania Chetcuti Zammit; Pierre Ellul; Natalia Pedersen; Jens Kjeldsen; Jóngerð Maria Miné Midjord; Kári Rubek Nielsen; Karina Winther Andersen; Vibeke Andersen; Konstantinos H Katsanos; Dimitrios K Christodoulou; Viktor Domislovic; Zeljko Krznaric; Shaji Sebastian; Pia Oksanen; Pekka Collin; Luisa Barros; Fernando Magro; Riina Salupere; Hendrika Adriana Linda Kievit; Adrian Goldis; Ioannis P Kaimakliotis; Jens F Dahlerup; Carl Eriksson; Jonas Halfvarson; Alberto Fernandez; Vicent Hernandez; Svetlana Turcan; Elena Belousova; Ebbe Langholz; Pia Munkholm; Selwyn Odes Journal: Lancet Gastroenterol Hepatol Date: 2020-02-13
Authors: C B Larmonier; J K Uno; Kang-Moon Lee; T Karrasch; D Laubitz; R Thurston; M T Midura-Kiela; F K Ghishan; R B Sartor; C Jobin; P R Kiela Journal: Am J Physiol Gastrointest Liver Physiol Date: 2008-09-25 Impact factor: 4.052
Authors: Moritz Leppkes; Christoph Becker; Ivaylo I Ivanov; Sebastian Hirth; Stefan Wirtz; Clemens Neufert; Sandrine Pouly; Andrew J Murphy; David M Valenzuela; George D Yancopoulos; Burkhard Becher; Dan R Littman; Markus F Neurath Journal: Gastroenterology Date: 2008-10-09 Impact factor: 22.682